Source comparison
CJC-1295 no DAC & Ipamorelin: Results Comparison
IGF-1 Level Increase (% from baseline) +8–12% +18–28% +30–50% Statistically significant after day 10; anabolic threshold reached by week 3 Meaningful marker only if baseline IGF-1 was measured pre-protocol Lean Mass Gain (pounds) +0.2–0.8 +1.0–2.5 +1.5–4.5 Mod
This comparison does not assign a generated winner or score.
- IGF-1 Level Increase (% from baseline)
- +8–12%
- +18–28%
- +30–50%
- Statistically significant after day 10; anabolic threshold reached by week 3
- Meaningful marker only if baseline IGF-1 was measured pre-protocol
- Lean Mass Gain (pounds)
- +0.2–0.8
- +1.0–2.5
- +1.5–4.5
- Modest but measurable via DEXA; most gain is glycogen and hydration, not myofibrillar hypertrophy
- Weight alone is a poor proxy. Composition testing required
- Deep Sleep Duration (minutes gained per night)
- +6–12
- +10–18
- +15–25
- Correlates with GH pulse amplitude; measurable via wearables or polysomnography
- First noticeable benefit for most users; often precedes other changes
- Recovery Time Between Training Sessions (% reduction)
- −5–10%
- −12–18%
- −20–30%
- Athletes report ability to train same muscle groups with less rest by week 3
- Subjective but consistent across cohorts; performance proxy for GH activity
- Fat Loss (pounds)
- −0.1–0.5
- −0.3–1.0
- −0.5–1.8
- Modest direct lipolytic effect; more pronounced in caloric deficit
- Not a primary outcome at 30 days. Expect this after 8–12 weeks